SWShuxuan Wu

Shuxuan Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shuxuan Wu has a total of 2 co-authors. Here are the top co-authors by number of shared publications:

  • Rong Mei

    Department of Anesthesiology, Jinlong hospital, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi City, Hubei Province, China

    1 shared publication
  • Wei Zhang

    Department of Anesthesiology, Jinlong hospital, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi City, Hubei Province, China

    1 shared publication

Latest Publications

  • Ketorolac tromethamine represses senescence in aging articular chondrocytes

    by Wei Zhang, Rong Mei, Shuxuan Wu

    The present study aims to explore the potential function of ketorolac tromethamine in treating osteoarthritis (OA) by examining its effects on interleukin-1β (IL-1β)-triggered cellular senescence in chondrocytes. More β-galactosidase (SA-β-Gal) positively stained cells, promoted cell fraction in the G0/G1 phase, increased release of matrix metalloproteinase (MMP)-3 and MMP-13, and upregulated cellular senescence-related genes (p21 and p53) were observed in IL-1β-challenged HC-A cells, all of which were significantly reversed by 25 and 50 mg/mL ketorolac tromethamine. Furthermore, the upregulated cyclooxygenase-2 (COX-2) and elevated release of prostaglandin E2 (PGE2) in IL-1β- challenged HC-A cells were dramatically repressed by ketorolac tromethamine. Lastly, the inhibitory effects of ketorolac tromethamine on the activation of β-galactosidase and the upregulation of p21 and p53 were greatly abolished by the overexpression of COX-2. Collectively, ketorolac tromethamine repressed cellular senescence in aging articular chondrocytes by inhibiting COX-2.